Medical Information

Enasidenib is not suitable for all populations. For patients with specific physical conditions, the use of this medication may pose serious risks and requires special attention or prohibition.

1、 Notice for patients with severe liver and kidney dysfunction

1. Severe liver dysfunction

Enasidenib is contraindicated for patients with significantly elevated total bilirubin or severe liver damage. The use of this drug in such patients may increase the metabolic burden on the liver, leading to drug accumulation and increased toxicity.

2. Severe renal dysfunction

At present, there is a lack of safety and pharmacokinetic data for patients with severe renal insufficiency (such as creatinine clearance rate below 30mL/min) using Enasidib, and its use is generally not recommended.

3. Screening is necessary before medication

Before starting treatment, a comprehensive liver and kidney function test must be completed. If there is mild to moderate damage, the doctor should weigh the pros and cons before deciding whether to use medication, and closely monitor relevant indicators during the treatment period.

2、 Notice for pregnant women and those preparing for pregnancy

1. Pregnant women are prohibited from using it

Based on animal research results and mechanisms of action, Enasidenib can cause harm to fetuses and is contraindicated for pregnant women.

2. Pre treatment pregnancy testing

Women with fertility must undergo a pregnancy test within 7 days before starting treatment to confirm a negative result before initiating treatment.

3. Requirements for efficient contraception

Women of childbearing age must use highly effective contraceptive measures during treatment and for at least 2 months after discontinuing medication. If a male patient's partner has fertility, contraceptive measures should also be taken during the treatment period and within 2 months after discontinuation of medication.

4. Not recommended during lactation

It is not yet clear whether Enasidenib is secreted through breast milk. Due to potential risks, breastfeeding is not recommended during treatment and for 2 months after discontinuation.

3、 Other precautions

1. Allergy history notification

Individuals who are allergic to Enasidib or any of its excipients are prohibited from using it.

2. Combination medication should be taken with caution

Before use, it is necessary to inform the doctor of all medications being taken to avoid potential drug interactions and increased risks.

3. Timely communication

If you become pregnant or plan to become pregnant during medication, you must immediately inform your doctor and do not stop or continue medication without authorization.